The Novel Oral Syk Inhibitor, Bl1002494, Protects Mice From Arterial Thrombosis and Thromboinflammatory Brain Infarction | Zendy

Judith M.M. van Eeuwijk | Zendy; David Stegner | Zendy; David Lamb | Zendy; Peter Kraft | Zendy; Sarah Beck | Zendy; Ina Thielmann | Zendy; Friedemann Kiefer | Zendy; Barbara Walzog | Zendy; Guido Stoll | Zendy; Bernhard Nieswandt | Zendy

Open Access

The Novel Oral Syk Inhibitor, Bl1002494, Protects Mice From Arterial Thrombosis and Thromboinflammatory Brain Infarction

Author(s) -

Judith M.M. van Eeuwijk,

David Stegner,

David Lamb,

Peter Kraft,

Sarah Beck,

Ina Thielmann,

Friedemann Kiefer,

Barbara Walzog,

Guido Stoll,

Bernhard Nieswandt

Publication year - 2016

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.115.306883

Subject(s) - syk , gpvi , medicine , thrombosis , stroke (engine) , thrombus , hemostasis , platelet , platelet activation , platelet membrane glycoprotein , receptor , tyrosine kinase , mechanical engineering , engineering

Ischemic stroke, which is mainly caused by thromboembolic occlusion of brain arteries, is the second leading cause of death and disability worldwide with limited treatment options. The platelet collagen receptor glycoprotein VI (GPVI) is a key player in arterial thrombosis and a critical determinant of stroke outcome, making its signaling pathway an attractive target for pharmacological intervention. The spleen tyrosine kinase (Syk) is an essential signaling mediator downstream of not only GPVI but also other platelet and immune cell receptors. We sought to assess whether Syk might be an effective antithrombotic target.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research